Switch theme
Sign up to access all valuation multiples
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.
2001
n/a
LTM Revenue $297M
LTM EBITDA $120M
$3.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PharmaResearch has a last 12-month revenue (LTM) of $297M and a last 12-month EBITDA of $120M.
In the most recent fiscal year, PharmaResearch achieved revenue of $255M and an EBITDA of $97.5M.
PharmaResearch expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmaResearch valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $297M | XXX | $255M | XXX | XXX | XXX |
| Gross Profit | $215M | XXX | $183M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $120M | XXX | $97.5M | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 38% | XXX | XXX | XXX |
| EBIT | $110M | XXX | $91.6M | XXX | XXX | XXX |
| EBIT Margin | 37% | XXX | 36% | XXX | XXX | XXX |
| Net Profit | $84.5M | XXX | $66.9M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, PharmaResearch's stock price is KRW 451000 (or $328).
PharmaResearch has current market cap of KRW 4.67T (or $3.4B), and EV of KRW 4.22T (or $3.1B).
See PharmaResearch trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1B | $3.4B | XXX | XXX | XXX | XXX | $7.87 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, PharmaResearch has market cap of $3.4B and EV of $3.1B.
PharmaResearch's trades at 12.1x EV/Revenue multiple, and 31.5x EV/EBITDA.
Equity research analysts estimate PharmaResearch's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaResearch has a P/E ratio of 40.1x.
See valuation multiples for PharmaResearch and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $3.1B | XXX | $3.1B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | 12.1x | XXX | XXX | XXX |
| EV/EBITDA | 25.5x | XXX | 31.5x | XXX | XXX | XXX |
| EV/EBIT | 27.9x | XXX | 33.5x | XXX | XXX | XXX |
| EV/Gross Profit | 14.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.1x | XXX | 50.7x | XXX | XXX | XXX |
| EV/FCF | 39.2x | XXX | 42.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharmaResearch's last 12 month revenue growth is 33%
PharmaResearch's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
PharmaResearch's rule of 40 is 77% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaResearch's rule of X is 123% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for PharmaResearch and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Margin | 40% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | 32% | XXX | XXX | XXX |
| Rule of 40 | 77% | XXX | 71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 123% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaResearch acquired XXX companies to date.
Last acquisition by PharmaResearch was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmaResearch acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was PharmaResearch founded? | PharmaResearch was founded in 2001. |
| Where is PharmaResearch headquartered? | PharmaResearch is headquartered in South Korea. |
| Who is the CEO of PharmaResearch? | PharmaResearch's CEO is Mr. Ki-seok Kang. |
| Is PharmaResearch publicy listed? | Yes, PharmaResearch is a public company listed on KRX. |
| What is the stock symbol of PharmaResearch? | PharmaResearch trades under 214450 ticker. |
| When did PharmaResearch go public? | PharmaResearch went public in 2015. |
| Who are competitors of PharmaResearch? | Similar companies to PharmaResearch include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of PharmaResearch? | PharmaResearch's current market cap is $3.4B |
| What is the current revenue of PharmaResearch? | PharmaResearch's last 12 months revenue is $297M. |
| What is the current revenue growth of PharmaResearch? | PharmaResearch revenue growth (NTM/LTM) is 33%. |
| What is the current EV/Revenue multiple of PharmaResearch? | Current revenue multiple of PharmaResearch is 10.3x. |
| Is PharmaResearch profitable? | Yes, PharmaResearch is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PharmaResearch? | PharmaResearch's last 12 months EBITDA is $120M. |
| What is PharmaResearch's EBITDA margin? | PharmaResearch's last 12 months EBITDA margin is 40%. |
| What is the current EV/EBITDA multiple of PharmaResearch? | Current EBITDA multiple of PharmaResearch is 25.5x. |
| What is the current FCF of PharmaResearch? | PharmaResearch's last 12 months FCF is $78.2M. |
| What is PharmaResearch's FCF margin? | PharmaResearch's last 12 months FCF margin is 26%. |
| What is the current EV/FCF multiple of PharmaResearch? | Current FCF multiple of PharmaResearch is 39.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
